Robert J. Glynn - Concepedia

Author

Robert J. Glynn

Also Known As

Avorn, J., Avorn, Jerry, Brookhart, M. Alan, C Mack, Elizabeth M. Garry, Glynn, R.J., Glynn, Robert J., Haneuse, S., Irena Trbojevic-Akmacic, Kwon, Jun Soo

798

Publications

85.1K

Citations

138

H-Index

365

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Massachusetts General Hospital

About

Robert J. Glynn is an author at Brigham and Women's Hospital specializing in medicine, public health, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	17	23	2K
2	Engineering	7	7	480
3	Business	3	3	469
4	Arts	1	1	11
5	Education	1	1	61

Robert J. Glynn

467

Publications

78.2K

Citations

128

H-Index

Page 1

	Year	Citations
A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission Jack M. Guralnik, E. M. Simonsick, Luigi Ferrucci, Journal of Gerontology	1994	9.4K
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2008	6.5K
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Obstetrical & Gynecological Survey Vascular DiseaseElevated C-reactive ProteinUnstable AnginaHyperlipidemiaPharmacotherapy	2009	3.7K
Variable Selection for Propensity Score Models M. Alan Brookhart, Sebastian Schneeweiß, Kenneth J. Rothman, American Journal of Epidemiology Propensity ScoreEpidemiologyPreventive MedicineSelection BiasVariable Selection Problem	2006	2.2K
High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data Sebastian Schneeweiß, Jeremy A. Rassen, Robert J. Glynn, Epidemiology	2009	1.1K
C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction Paul M. Ridker, Robert J. Glynn, Charles H. Hennekens Circulation	1998	1K
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, The Lancet Jupiter TrialCardiovascular DiseaseHyperlipidemiaLdl CholesterolDyslipidemia	2009	1K
A combined comorbidity score predicted mortality in elderly patients better than existing scores Joshua J. Gagne, Robert J. Glynn, Jerry Avorn, Journal of Clinical Epidemiology Health PolicyGeriatricsLongevityElderly PatientsCombined Comorbidity Score	2011	980
Asymptomatic hyperuricemia. Risks and consequences in the normative aging study Edward W. Campion, Robert J. Glynn, Lorraine O. Delabry The American Journal of Medicine AgingGeriatricsLongevityMedicinePhysiology	1987	851
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Paul M. Ridker, Jean MacFadyen, Peter Libby, The Lancet Cardiovascular ToxicityC-reactive Protein ReductionCardiovascular DiseaseCardiovascular PharmacologyEvent Reduction	2017	847

Page 1